Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 46fludarabine phosphate 34Peripheral Blood Stem Cell Transplantation 29Whole-Body Irradiation 22Etoposide 22Tacrolimus 20Methotrexate 20Mycophenolic Acid 19Cytarabine 19Dexamethasone 17Vincristine 16Filgrastim 16Busulfan 16venetoclax 15Antilymphocyte Serum 15Rituximab 13Prednisone 13Cyclosporine 12Doxorubicin 11Melphalan 9Calcium Dobesilate 9nelarabine 8Bortezomib 8merphos 7Radiotherapy 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7prednylidene 6pegaspargase 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × CVAD protocol × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡